Rekvina Labs, a company in the Pharmaceuticals industry, reported revenue of ₹0.59 crore and a net loss of ₹0.05 crore for the September 2026 quarter.
Rekvina Labs (BSE: VINRKLB) closed at ₹80.17 on 20 Nov 2026. Its market capitalisation is ₹89 crore.
Rekvina Laboratories Limited is engaged in the manufacturing and marketing of pharmaceutical formulations.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.